(Q33256941)

24 July 2017

1 reference

title

Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia (English)

1 reference

24 July 2017

2

Kai-Uwe Eckardt

1 reference

24 July 2017

Iain C Macdougall

1

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

24 July 2017

1 reference

24 July 2017

volume

368

1 reference

24 July 2017

issue

9539

1 reference

24 July 2017

page(s)

947-953

1 reference

Erythropoietin: structure, control of production, and function

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Erythropoietin receptors: their role beyond erythropoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Cloning and expression of the human erythropoietin gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

The molecular biology of erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Pure red-cell aplasia and epoetin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Follow-on biologics: challenges of the "next generation".

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Development and characterization of novel erythropoiesis stimulating protein (NESP)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Small peptides as potent mimetics of the protein hormone erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Erythropoietin mimetic peptides and the future

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Mimicry of erythropoietin by a nonpeptide molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

The critical role of SRC homology domain 2-containing tyrosine phosphatase-1 in recombinant human erythropoietin hyporesponsive anemia in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Oxygen sensing by HIF hydroxylases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

HIF-1: an oxygen response system with special relevance to the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Human artificial chromosome (HAC) vector provides long-term therapeutic transgene expression in normal human primary fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Human erythropoietin gene therapy for patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

The regulated long-term delivery of therapeutic proteins by using antigen-specific B lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Erythropoietin therapy for acute stroke is both safe and beneficial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Erythropoietin for neurologic protection and diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

A novel protective effect of erythropoietin in the infarcted heart

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Pleiotropic renal actions of erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

Derivatives of erythropoietin that are tissue protective but not erythropoietic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969120-4

7 January 2021

10.1016/S0140-6736(06)69120-4

Identifiers

DOI

1 reference

24 July 2017

1 reference